Defining the optimal timing of adjuvant therapy for resected pancreatic cancer: A statewide cancer registry analysis.
Hayder Saeed(University of Kentucky), Ching‐Wei D. Tzeng(The University of Texas MD Anderson Cancer Center), Dima Hnoosh(University of Kentucky), Patrick C. McGrath(University of Kentucky), Mahesh Kudrimoti(University of Kentucky), Eric B. Durbin(University of Kentucky), Peter J. Hosein(Markey Cancer Center), Philip A. DeSimone(Markey Cancer Center), Bin Huang(North Sichuan Medical University), Erin Maynard, Lowell Anthony(University of Kentucky)
Cited by 0
Related Papers
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
|The Lancet Oncology|2016|914
Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.
|PubMed|2005|375
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium
|Annals of Oncology|2021|328
Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis
|JNCI Journal of the National Cancer Institute|2019|299
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial
|The Lancet. Gastroenterology & hepatology|2022|255